［1］中国抗癌协会血液肿瘤专业委员会，中华医学会血液学分会白血病淋巴瘤学组.中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版).中华血液学杂志，2016，37 (10): 837-845.

［2］ NCCN Clinical Practice Guidelines in Oncology-Acute Lymphoblastic Leukemia (2019 Version 2) [DB/OL]. http: //www. nccn. org.

［3］ ARBER DA, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia. Blood, 2016, 127: 2391-2405.

［4］ BASSAN R, HOELZER D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol, 2011, 29: 532-543.

［5］ COUSTAN-SMITH E, MULLIGHAN CG, ONCIU M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol, 2009, 10: 147-156.

［6］ ROBERTS KG, GU Z, PAYNE-TURNER D, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol, 2017, 35: 394-401.

［7］ ROBERTS KG, LI Y, PAYNE-TURNER D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med, 2014, 371 (11): 1005-1015.

［8］ HEROLD T, GÖKBUGET N. Philadelphia-like acute lymphoblastic leukemia in adults. Curr Oncol Rep, 2017, 19 (5): 31.

［9］ RYTTING ME, JABBOUR EJ, O’BRIEN SM, et al. Acute lymphoblastic leukemia in adolescents and young adults. Cancer, 2017, 123 (13): 2398-2403.

［10］ MAUDE SL, LAETSCH TW, BUECHNER J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med, 2018, 378 (5): 439-448.

［11］ O’DWYER KM, LIESVELD JL. Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies. Best Pract Res Clin Haematol, 2017, 30 (3): 184-192.

［12］ PUI CH, PEI D, CAMPANA D, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol, 2011, 29 (4): 386-391.

［13］ BARRY E, DEANGELO DJ, NEUBERG D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol, 2007, 25 (7): 813-819.

［14］ HUGUET F, LEGUAY T, RAFFOUX E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol, 2009, 27 (6): 911-918.

［15］ RIBERA JM, ORIOL A, SANZ MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol, 2008, 26 (11):1843-1849.

［16］ TOFT N, BIRGENS H, ABRAHAMSSON J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia, 2018, 32 (3): 606-615.

［17］ KANTARJIAN H, THOMAS D, O’BRIEN S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer, 2004, 101 (12): 2788-2801.

［18］ O′BRIEN S, THOMAS DA, RAVANDI F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer, 2008, 113 (8): 2097-2101.

［19］ RYTTING ME, JABBOUR EJ, JORGENSEN JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol, 2016, 91 (8): 819-823.

［20］ SIVE JI, BUCK G, FIELDING A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol, 2012, 157 (4): 463-471.

［21］ ROWE JM, BUCK G, BURNETT AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood, 2005, 106 (12): 3760-3767.

［22］ MARTELL MP, ATENAFU EG, MINDEN MD, et al. Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. Br J Haematol, 2013, 163 (4): 458-464.

［23］ KANTARJIAN HM, DEANGELO DJ, STELLJES M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med, 2016, 375 (8): 740-753.

［24］ GUPTA V, RICHARDS S, ROWE J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in fi rst remission: an individual patient data meta-analysis. Blood, 2013, 121 (2): 339-350.

［25］ DE LABARTHE A, ROUSSELOT P, HUGUET-RIGAL F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood, 2007, 109 (4): 1408-1413.

［26］ OTTMANN OG, WASSMANN B, PFEIFER H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) . Cancer, 2007, 109 (10): 2068-2076.

［27］ VIGNETTI M, FAZI P, CIMINO G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell′Adulto (GIMEMA) LAL0201-B protocol. Blood, 2007, 109 (9): 3676-3678.

［28］ DAVER N, THOMAS D, RAVANDI F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 2015, 100 (5): 653-661.

［29］ CHALANDON Y, THOMAS X, HAYETTE S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood, 2015, 125 (24): 3711-3719.

［30］ SASAKI K, JABBOUR EJ, RAVANDI F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2016, 122 (23): 3650-3656.

［31］ ROUSSELOT P, COUDÉ MM, GOKBUGET N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood, 2016, 128 (6): 774-782.